GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Current Accrued Expense
中文

Ocumension Therapeutics (HKSE:01477) Current Accrued Expense

: HK$0.0 Mil (As of Jun. 2023)
View and export this data going back to 2020. Start your Free Trial

Ocumension Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2023 was HK$0.0 Mil.


Ocumension Therapeutics Current Accrued Expense Historical Data

The historical data trend for Ocumension Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocumension Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Ocumension Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines